blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2984184

EP2984184 - USE OF DNQ OR DNQ-87 IN COMBINATION WITH A PARP1 INHIBITOR FOR THE TREATMENT OF CANCER [Right-click to bookmark this link]
Former [2016/07]TUMOR-SELECTIVE COMBINATION THERAPY
[2020/25]
StatusNo opposition filed within time limit
Status updated on  01.10.2021
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  23.10.2020
FormerGrant of patent is intended
Status updated on  14.06.2020
FormerExamination is in progress
Status updated on  15.12.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
The Board of Trustees of the University of Illinois
352 Henry Administration Building
506 South Wright Street
Urbana, IL 61801 / US
For all designated states
The Board of Regents of the University of Texas System
210 West 7th Street
Austin, TX 78701 / US
[2021/07]
Former [2016/07]For all designated states
The Board of Trustees of the University of Illinois
352 Henry Administration Building
506 South Wright Street
Urbana, IL 61801 / US
For all designated states
The Board of Regents of The University of Texas System
201 West 7th Street
Austin, TX 78701 / US
Inventor(s)01 / HERGENROTHER, Paul J.
2607 Wedgewood Drive
Champaign Illinois 61822 / US
02 / BOOTHMAN, David A.
6834 Mimosa Lane
Dallas Texas 75230 / US
03 / BAIR, Joseph S.
209 Lincoln Mill Rd
Mullica Hill, NJ 08062 / US
04 / CAO, Lifen
5720 Forest Park Road
Apt. 1508
Dallas Texas 75235 / US
05 / GAO, Jimming
3200 Prestonwood Drive
Plano Texas 75093 / US
06 / HUANG, Xiumei
6401 Maple Avenue
Apt. 9302
Dallas Texas 75235 / US
07 / LUO, Xiuquan
8412 Halliford Court
Plano Texas 75024 / US
08 / MA, Xinpeng
10809 North Central Expressway
Apt. 3250
Dallas Texas 75231 / US
09 / MOORE, Zachary R.
2929 Wycliff Avenue
Apt. 2243
Dallas Texas 75219 / US
10 / PARKINSON, Elizabeth I.
1735 Valley Road
Apt. C
Champaign Illinois 61820 / US
 [2020/48]
Former [2016/07]01 / HERGENROTHER, Paul J.
2607 Wedgewood Drive
Champaign Illinois 61822 / US
02 / BOOTHMAN, David A.
6834 Mimosa Lane
Dallas Texas 75230 / US
03 / BAIR, Joseph S.
209 Lincoln Mill Road
Millica Hill, NJ 08062 / US
04 / CAO, Lifen
5720 Forest Park Road
Apt. 1508
Dallas Texas 75235 / US
05 / GAO, Jimming
3200 Prestonwood Drive
Plano Texas 75093 / US
06 / HUANG, Xiumei
6401 Maple Avenue
Apt. 9302
Dallas Texas 75235 / US
07 / LUO, Xiuquan
8412 Halliford Court
Plano Texas 75024 / US
08 / MA, Xinpeng
10809 North Central Expressway
Apt. 3250
Dallas Texas 75231 / US
09 / MOORE, Zachary R.
2929 Wycliff Avenue
Apt. 2243
Dallas Texas 75219 / US
10 / PARKINSON, Elizabeth I.
1735 Valley Road
Apt. C
Champaign Illinois 61820 / US
Representative(s)Rückerl, Florian
Dehmel & Bettenhausen
Patentanwälte PartmbB
Herzogspitalstraße 11
80331 München / DE
[2020/48]
Former [2016/07]Rückerl, Florian
Dehmel und Bettenhausen
Herzogspitalstraße 11
80331 München / DE
Application number, filing date14783210.908.04.2014
[2016/07]
WO2014US33400
Priority number, dateUS201361810008P09.04.2013         Original published format: US 201361810008 P
[2016/07]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014168991
Date:16.10.2014
Language:EN
[2014/42]
Type: A1 Application with search report 
No.:EP2984184
Date:17.02.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 16.10.2014 takes the place of the publication of the European patent application.
[2016/07]
Type: B1 Patent specification 
No.:EP2984184
Date:25.11.2020
Language:EN
[2020/48]
Search report(s)International search report - published on:US16.10.2014
(Supplementary) European search report - dispatched on:EP02.11.2016
ClassificationIPC:A61K31/353, A61K31/352, A61K31/706, C12Q1/68, A61K45/06, A61P35/00, A61K31/131, A61K31/4738, A61K31/4745
[2016/48]
CPC:
A61K31/706 (EP,US); C12Q1/68 (MX); A61K31/131 (EP,MX,US);
A61K31/352 (MX); A61K31/353 (EP,MX,US); A61K31/4738 (EP,MX,US);
A61K31/4745 (EP,MX,US); A61K45/06 (EP,MX,US); A61P35/00 (EP);
A61P43/00 (EP); C12Q1/6886 (EP,MX,US); C12Q2600/106 (EP,MX,US);
C12Q2600/158 (EP,MX,US) (-)
C-Set:
A61K31/131, A61K2300/00 (US,EP);
A61K31/353, A61K2300/00 (EP,US);
A61K31/4738, A61K2300/00 (US,EP)
Former IPC [2016/07]C12Q1/68, A61K31/352, A61K45/06
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/07]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERWENDUNG VON DNQ ODER DNQ-87 IN KOMBINATION MIT EINEM PARP1 HEMMER ZUR BEHANDLUNG VON KREBS[2020/25]
English:USE OF DNQ OR DNQ-87 IN COMBINATION WITH A PARP1 INHIBITOR FOR THE TREATMENT OF CANCER[2020/25]
French:UTILISATION DE DNQ OU DNQ-87 EN COMBINAISON AVEC UN INHIBITEUR DE LA PARP1 POUR LE TRAITEMENT DU CANCER[2020/25]
Former [2016/07]TUMORSELEKTIVE KOMBINATIONSTHERAPIE
Former [2016/07]TUMOR-SELECTIVE COMBINATION THERAPY
Former [2016/07]POLYTHÉRAPIE POUR TUMEUR SÉLECTIVE
Entry into regional phase06.11.2015National basic fee paid 
06.11.2015Search fee paid 
06.11.2015Designation fee(s) paid 
06.11.2015Examination fee paid 
Examination procedure06.11.2015Examination requested  [2016/07]
11.05.2017Amendment by applicant (claims and/or description)
14.12.2017Despatch of a communication from the examining division (Time limit: M06)
22.06.2018Reply to a communication from the examining division
21.03.2019Despatch of a communication from the examining division (Time limit: M02)
23.05.2019Reply to a communication from the examining division
12.11.2019Despatch of a communication from the examining division (Time limit: M02)
13.01.2020Reply to a communication from the examining division
15.06.2020Communication of intention to grant the patent
15.10.2020Fee for grant paid
15.10.2020Fee for publishing/printing paid
15.10.2020Receipt of the translation of the claim(s)
Opposition(s)26.08.2021No opposition filed within time limit [2021/44]
Fees paidRenewal fee
29.02.2016Renewal fee patent year 03
10.04.2017Renewal fee patent year 04
11.04.2018Renewal fee patent year 05
15.04.2019Renewal fee patent year 06
15.06.2020Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL25.11.2020
CY25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
MC25.11.2020
MK25.11.2020
MT25.11.2020
RO25.11.2020
RS25.11.2020
SI25.11.2020
SK25.11.2020
SM25.11.2020
BG25.02.2021
NO25.02.2021
IS25.03.2021
LU08.04.2021
[2024/41]
Former [2024/22]AL25.11.2020
CY25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
MC25.11.2020
MK25.11.2020
RO25.11.2020
RS25.11.2020
SI25.11.2020
SK25.11.2020
SM25.11.2020
BG25.02.2021
NO25.02.2021
IS25.03.2021
LU08.04.2021
Former [2023/30]AL25.11.2020
CY25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
MC25.11.2020
RO25.11.2020
RS25.11.2020
SI25.11.2020
SK25.11.2020
SM25.11.2020
BG25.02.2021
NO25.02.2021
IS25.03.2021
LU08.04.2021
Former [2022/23]AL25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
MC25.11.2020
RO25.11.2020
RS25.11.2020
SI25.11.2020
SK25.11.2020
SM25.11.2020
BG25.02.2021
NO25.02.2021
IS25.03.2021
LU08.04.2021
Former [2022/10]AL25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
MC25.11.2020
RO25.11.2020
RS25.11.2020
SI25.11.2020
SK25.11.2020
SM25.11.2020
BG25.02.2021
NO25.02.2021
LU08.04.2021
Former [2022/04]AL25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
MC25.11.2020
RO25.11.2020
RS25.11.2020
SI25.11.2020
SK25.11.2020
SM25.11.2020
BG25.02.2021
NO25.02.2021
IS25.03.2021
LU08.04.2021
Former [2021/50]AL25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
MC25.11.2020
RO25.11.2020
RS25.11.2020
SI25.11.2020
SK25.11.2020
SM25.11.2020
BG25.02.2021
NO25.02.2021
IS25.03.2021
Former [2021/45]AL25.11.2020
EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
RO25.11.2020
RS25.11.2020
SK25.11.2020
SM25.11.2020
BG25.02.2021
NO25.02.2021
IS25.03.2021
Former [2021/36]EE25.11.2020
FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
RO25.11.2020
RS25.11.2020
SK25.11.2020
SM25.11.2020
BG25.02.2021
NO25.02.2021
IS25.03.2021
Former [2021/35]FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
RO25.11.2020
RS25.11.2020
SK25.11.2020
SM25.11.2020
BG25.02.2021
NO25.02.2021
IS25.03.2021
Former [2021/33]FI25.11.2020
HR25.11.2020
LT25.11.2020
LV25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
NO25.02.2021
IS25.03.2021
Former [2021/32]FI25.11.2020
HR25.11.2020
LV25.11.2020
RS25.11.2020
SM25.11.2020
BG25.02.2021
NO25.02.2021
IS25.03.2021
Former [2021/28]FI25.11.2020
HR25.11.2020
LV25.11.2020
RS25.11.2020
BG25.02.2021
NO25.02.2021
IS25.03.2021
Former [2021/25]FI25.11.2020
LV25.11.2020
RS25.11.2020
BG25.02.2021
NO25.02.2021
IS25.03.2021
Former [2021/24]FI25.11.2020
LV25.11.2020
RS25.11.2020
BG25.02.2021
NO25.02.2021
Former [2021/23]FI25.11.2020
LV25.11.2020
RS25.11.2020
NO25.02.2021
Former [2021/22]FI25.11.2020
RS25.11.2020
NO25.02.2021
Former [2021/20]FI25.11.2020
Documents cited:Search[Y]US2013030237  (THEUER CHARLES [US]) [Y] 1-15 * paragraph [0027]; claims 1,7, 9, 17, *;
 [Y]  - X. HUANG ET AL, "An NQO1 Substrate with Potent Antitumor Activity That Selectively Kills by PARP1-Induced Programmed Necrosis", CANCER RESEARCH, (20120615), vol. 72, no. 12, doi:10.1158/0008-5472.CAN-11-3135, ISSN 0008-5472, pages 3038 - 3047, XP055187225 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-11-3135
 [Y]  - JOSEPH S. BAIR ET AL, "Chemistry and Biology of Deoxynyboquinone, a Potent Inducer of Cancer Cell Death", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (20100421), vol. 132, no. 15, doi:10.1021/ja100610m, ISSN 0002-7863, pages 5469 - 5478, XP055187222 [Y] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1021/ja100610m
International search[A]US4906562  (HELLSTROM INGEGERD [US], et al);
 [A]US5716963  (AVENDAO LOPEZ CARMEN [ES], et al);
 [Y]US2002198264  (GERSON STANTON L [US], et al);
 [A]US2004001871  (BOOTHMAN DAVID [US], et al);
 [A]US6809096  (DELFOURNE EVELYNE [FR], et al);
 [A]US2005175668  (BOOTHMAN DAVID [US], et al);
 [A]US2009163570  (MIREJOVSKY DORLA [US], et al);
 [Y]US2009275608  (OSSOVSKAYA VALERIA S [US], et al);
 [X]WO2012040492  (UNIV TEXAS [US], et al);
 [A]US2012142650  (HOLLINGSWORTH JOHN [US], et al);
 [A]US2012208767  (JAISWAL ANIL K [US])
by applicantUS6833373
 WO2012040492
 US2013030237
 WO2013056073
    - BLANCOBOOTHMANGAO et al., Cancer Res., (20100000), vol. 70, page 3896
    - HUANG et al., Cancer Res., (20120615), vol. 72, no. 12, pages 3038 - 3047
    - BAIR et al., J Am Chem Soc., (20100421), vol. 132, no. 15, pages 5469 - 5478
    - IAN T. HARRISONSHUYEN HARRISON, Compendium of Organic Synthetic Methods, John Wiley & Sons, (19710000), vol. 1
    - IAN T. HARRISONSHUYEN HARRISON, COMPENDIUM OF ORGANIC SYNTHETIC METHODS, (19840000), vol. 6
    - Comprehensive Organic Synthesis; Selectivity, Strategy & Efficiency in Modern Organic Chemistry, Pergamon Press, (19930000), vol. 9
    - Remington's Pharmaceutical Sciences, Mack Printing Company, (19900000), pages 1289 - 1329
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.